Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer†.

Takenaka T, Takenoyama M, Yamaguchi M, Toyozawa R, Inamasu E, Kojo M, Toyokawa G, Yoshida T, Shiraishi Y, Morodomi Y, Hirai F, Taguchi K, Shimokawa M, Seto T, Ichinose Y.

Eur J Cardiothorac Surg. 2015 Mar;47(3):550-5. doi: 10.1093/ejcts/ezu227. Epub 2014 Jun 3.

PMID:
24894095
[PubMed - in process]
3.

Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.

Jeon JH, Kang CH, Kim HS, Seong YW, Park IK, Kim YT.

Eur J Cardiothorac Surg. 2015 Mar;47(3):556-62. doi: 10.1093/ejcts/ezu177. Epub 2014 Apr 22.

PMID:
24760387
[PubMed - in process]
4.

Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.

Saisho S, Yasuda K, Maeda A, Yukawa T, Okita R, Hirami Y, Shimizu K, Nakata M.

Interact Cardiovasc Thorac Surg. 2013 Feb;16(2):166-72. doi: 10.1093/icvts/ivs450. Epub 2012 Nov 9.

PMID:
23143203
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, Smit EF.

Lung Cancer. 2014 Jul;85(1):19-24. doi: 10.1016/j.lungcan.2014.03.016. Epub 2014 Mar 23.

PMID:
24768581
[PubMed - indexed for MEDLINE]
6.

The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.

Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH, Kim JH.

J Thorac Oncol. 2013 Feb;8(2):171-8. doi: 10.1097/JTO.0b013e318277a3bb.

PMID:
23287850
[PubMed - indexed for MEDLINE]
7.

Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.

Cha YK, Lee HY, Ahn MJ, Choi YL, Lee JH, Park K, Lee KS.

Clin Lung Cancer. 2014 Nov 18. pii: S1525-7304(14)00238-1. doi: 10.1016/j.cllc.2014.11.002. [Epub ahead of print]

PMID:
25499173
[PubMed - as supplied by publisher]
8.

Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS.

JAMA. 2014 Apr 9;311(14):1430-7. doi: 10.1001/jama.2014.3314.

PMID:
24715074
[PubMed - indexed for MEDLINE]
9.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

PMID:
22982650
[PubMed - indexed for MEDLINE]
10.

Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.

Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.

J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.

PMID:
24736073
[PubMed - indexed for MEDLINE]
11.

EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.

Koo DH, Kim KP, Choi CM, Lee DH, Lee JC, Lee JS, Jang SJ, Kim SW.

Cancer Chemother Pharmacol. 2015 Jan;75(1):197-206. doi: 10.1007/s00280-014-2631-5. Epub 2014 Nov 25.

PMID:
25422153
[PubMed - in process]
12.

Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.

Ying H, Yang XD, Sun Z, Ning X, Wang Y, Bai C, Chen S, Wang Y.

Med Oncol. 2014 Oct;31(10):220. doi: 10.1007/s12032-014-0220-4. Epub 2014 Sep 13.

PMID:
25216867
[PubMed - in process]
13.

Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.

Sun JM, Rampal S, Lee G, Lee J, Choi YL, Parasuraman B, Guallar E, Cho J, Shim YM.

Lung Cancer. 2013 May;80(2):191-6. doi: 10.1016/j.lungcan.2013.01.009. Epub 2013 Feb 4.

PMID:
23384673
[PubMed - indexed for MEDLINE]
14.

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, Wu YL.

Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21.

PMID:
19381876
[PubMed - indexed for MEDLINE]
15.

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC.

J Clin Oncol. 2012 Feb 1;30(4):433-40. doi: 10.1200/JCO.2011.38.3224. Epub 2012 Jan 3.

PMID:
22215752
[PubMed - indexed for MEDLINE]
Free Article
16.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
[PubMed - indexed for MEDLINE]
Free Article
17.

The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.

Wu WS, Chen YM, Tsai CM, Shih JF, Lee YC, Perng RP, Whang-Peng J.

J Chin Med Assoc. 2013 Dec;76(12):682-5. doi: 10.1016/j.jcma.2013.08.006. Epub 2013 Sep 21.

PMID:
24064329
[PubMed - indexed for MEDLINE]
18.

Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.

Okami J, Taniguchi K, Higashiyama M, Maeda J, Oda K, Orita N, Koizumi K, Kodama K, Kato K.

Oncology. 2007;72(3-4):234-42. doi: 10.1159/000112947. Epub 2008 Jan 7.

PMID:
18176089
[PubMed - indexed for MEDLINE]
19.

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.

Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.

Ann Oncol. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4.

PMID:
23559152
[PubMed - indexed for MEDLINE]
Free Article
20.

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.

Cai L, Zhu JF, Zhang XW, Lin SX, Su XD, Lin P, Chen K, Zhang LJ.

J Neurooncol. 2014 Nov;120(2):423-30. doi: 10.1007/s11060-014-1570-7. Epub 2014 Aug 7.

PMID:
25098700
[PubMed - in process]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk